Your browser is no longer supported. Please, upgrade your browser.
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E34.85 EPS (ttm)7.91 Insider Own0.10% Shs Outstand259.82M Perf Week-1.01%
Market Cap73.43B Forward P/E24.48 EPS next Y11.26 Insider Trans-71.72% Shs Float258.05M Perf Month-5.36%
Income2.08B PEG1.42 EPS next Q2.22 Inst Own97.00% Short Float1.57% Perf Quarter1.24%
Sales5.40B P/S13.59 EPS this Y118.10% Inst Trans-0.08% Short Ratio2.32 Perf Half Y15.04%
Book/sh24.87 P/B11.09 EPS next Y19.78% ROA14.80% Target Price297.00 Perf Year57.05%
Cash/sh15.73 P/C17.52 EPS next 5Y24.57% ROE20.60% 52W Range165.23 - 306.08 Perf YTD25.92%
Dividend- P/FCF49.16 EPS past 5Y28.00% ROI14.70% 52W High-11.17% Beta0.90
Dividend %- Quick Ratio3.40 Sales past 5Y48.30% Gross Margin87.70% 52W Low64.55% ATR8.55
Employees3000 Current Ratio3.50 Sales Q/Q76.50% Oper. Margin22.20% RSI (14)42.35 Volatility2.86% 3.04%
OptionableYes Debt/Eq0.00 EPS Q/Q121.50% Profit Margin21.80% Rel Volume0.61 Prev Close275.71
ShortableYes LT Debt/Eq0.08 EarningsJul 30 AMC Payout0.00% Avg Volume1.74M Price271.88
Recom2.00 SMA20-5.29% SMA50-4.13% SMA20011.13% Volume412,013 Change-1.39%
Jul-31-20Reiterated H.C. Wainwright Buy $295 → $315
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $300
Apr-30-20Reiterated H.C. Wainwright Buy $270 → $295
Apr-28-20Downgrade RBC Capital Mkts Outperform → Sector Perform $250 → $260
Mar-04-20Initiated Barclays Overweight $271
Jan-31-20Downgrade Robert W. Baird Outperform → Neutral $210 → $230
Nov-19-19Upgrade Guggenheim Neutral → Buy $252
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-02-20 07:32AM  
Jul-31-20 12:33PM  
08:20AM  
06:42AM  
03:31AM  
Jul-30-20 07:32PM  
05:35PM  
04:01PM  
Jul-29-20 11:24AM  
Jul-27-20 12:10PM  
Jul-25-20 11:52AM  
10:04AM  
07:30AM  
Jul-24-20 07:47PM  
12:45PM  
Jul-23-20 12:33PM  
Jul-22-20 05:45PM  
04:48PM  
Jul-21-20 12:05PM  
Jul-20-20 09:00AM  
Jul-17-20 07:02AM  
Jul-16-20 01:47PM  
09:00AM  
08:00AM  
Jul-15-20 05:45PM  
Jul-12-20 06:42AM  
Jul-09-20 05:45PM  
Jul-08-20 01:35PM  
01:23PM  
08:17AM  
Jul-07-20 06:48PM  
02:49PM  
11:35AM  
10:00AM  
Jul-03-20 12:36PM  
Jul-02-20 05:45PM  
10:38AM  
Jul-01-20 09:43AM  
07:37AM  
Jun-30-20 08:34AM  
08:33AM  
07:36AM  
Jun-29-20 11:30AM  
09:12AM  
08:23AM  
Jun-26-20 10:10AM  
08:25AM  
08:20AM  
08:14AM  
07:55AM  
Jun-25-20 09:18AM  
Jun-24-20 05:45PM  
11:54AM  
09:15AM  
08:15AM  
Jun-23-20 12:01PM  
07:07AM  
Jun-22-20 11:59AM  
08:12AM  
Jun-18-20 05:50PM  
08:15AM  
Jun-17-20 03:45PM  
11:14AM  
11:05AM  
09:53AM  
05:58AM  
Jun-16-20 10:15AM  
09:50AM  
06:30AM  
06:20AM  
Jun-12-20 04:23PM  
03:41PM  
02:12PM  
11:30AM  
11:25AM  
08:00AM  
07:30AM  
02:30AM  
Jun-10-20 05:50PM  
05:24PM  
11:46AM  
07:57AM  
03:00AM  
Jun-09-20 04:25PM  
02:09PM  
Jun-08-20 12:29PM  
12:00PM  
Jun-07-20 01:43PM  
07:04AM  
Jun-06-20 12:29PM  
07:55AM  
Jun-05-20 08:02AM  
Jun-04-20 05:50PM  
11:41AM  
Jun-03-20 11:54AM  
10:02AM  
09:40AM  
Jun-02-20 10:53AM  
10:30AM  
Jun-01-20 03:28PM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, Chief Adm, Leg & BD OffJul 13Option Exercise90.292,125191,86628,963Jul 15 04:41 PM
Silva Paul MSVP & ControllerJul 13Option Exercise90.2986077,64915,792Jul 15 04:51 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffJul 13Sale292.052,125620,61026,838Jul 15 04:41 PM
Silva Paul MSVP & ControllerJul 13Sale292.03860251,14514,932Jul 15 04:51 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerJul 10Sale293.15700205,20616,126Jul 14 04:16 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerJul 07Option Exercise173.512,786483,40337,965Jul 09 04:13 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerJul 07Sale300.002,786835,80035,179Jul 09 04:13 PM
LEIDEN JEFFREY MExecutive ChairmanJun 30Sale286.1532,7929,383,3042,261Jul 02 04:15 PM
Bhatia Sangeeta N.DirectorJun 02Sale282.88952269,2985,695Jun 03 04:22 PM
Kewalramani ReshmaCEO & PresidentMay 15Sale284.179928,13226,626May 19 04:35 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 15Sale284.0012034,08012,738May 19 04:33 PM
Silva Paul MSVP & ControllerMay 15Sale284.0015142,88514,932May 19 04:31 PM
Sachdev AmitEVP, Chief Patient OfficerMay 15Sale284.415816,49635,103May 19 04:29 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 15Sale284.406819,33926,838May 19 04:28 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 15Sale283.9811332,08935,179May 19 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale284.378223,31828,902May 19 04:21 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 12Option Exercise187.531,304244,53930,206May 14 04:17 PM
LEIDEN JEFFREY MExecutive ChairmanMay 12Option Exercise137.5288,53212,174,639129,353May 14 04:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 12Sale287.331,304374,67828,902May 14 04:17 PM
LEIDEN JEFFREY MExecutive ChairmanMay 12Sale283.4794,37026,751,44034,983May 14 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 11Option Exercise187.531,304244,53928,142May 13 04:18 PM
Sachdev AmitEVP, Chief Patient OfficerMay 11Option Exercise131.8910,6651,406,60745,768May 13 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 11Sale286.001,304372,94426,838May 13 04:18 PM
Sachdev AmitEVP, Chief Patient OfficerMay 11Sale282.6110,6653,014,01435,103May 13 04:20 PM
SACHS BRUCE IDirectorMay 07Option Exercise70.5545,0003,174,52556,210May 08 04:24 PM
LEIDEN JEFFREY MExecutive ChairmanMay 07Option Exercise137.5288,53412,174,982135,190May 08 04:20 PM
LEIDEN JEFFREY MExecutive ChairmanMay 07Sale269.7894,36925,459,01340,821May 08 04:20 PM
SACHS BRUCE IDirectorMay 07Sale269.8045,00012,140,80611,210May 08 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 06Option Exercise155.571,222190,10730,124May 08 04:17 PM
Kewalramani ReshmaCEO & PresidentMay 06Option Exercise179.672,074372,63828,700May 08 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 06Option Exercise155.571,222190,10728,060May 08 04:22 PM
Sachdev AmitEVP, Chief Patient OfficerMay 06Option Exercise131.8966988,23435,772May 08 04:23 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 06Option Exercise174.06966168,14613,704May 08 04:28 PM
Silva Paul MSVP & ControllerMay 06Option Exercise169.381,076182,25516,008May 08 04:26 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 06Sale272.70966263,43112,738May 08 04:28 PM
Sachdev AmitEVP, Chief Patient OfficerMay 06Sale275.28669184,16235,103May 08 04:23 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 06Sale272.641,222333,16526,838May 08 04:22 PM
Kewalramani ReshmaCEO & PresidentMay 06Sale272.852,074565,88226,626May 08 04:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 06Sale272.661,222333,19528,902May 08 04:17 PM
Silva Paul MSVP & ControllerMay 06Sale272.741,076293,47214,932May 08 04:26 PM
Sachdev AmitEVP, Chief Patient OfficerMay 05Option Exercise131.8913,3561,761,52348,459May 06 04:43 PM
LEIDEN JEFFREY MExecutive ChairmanMay 05Option Exercise137.5288,53712,175,273141,028May 07 04:24 PM
Sachdev AmitEVP, Chief Patient OfficerMay 05Sale270.0113,3563,606,23235,103May 06 04:43 PM
LEIDEN JEFFREY MExecutive ChairmanMay 05Sale269.9494,37225,475,03746,656May 07 04:24 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 04Option Exercise86.521,553134,36636,732May 06 04:38 PM
Sachdev AmitEVP, Chief Patient OfficerMay 04Option Exercise112.9843,7524,942,96878,855May 06 04:43 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 04Option Exercise86.522,330201,59231,232May 06 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 04Option Exercise86.522,330201,59229,168May 06 04:25 PM
Silva Paul MSVP & ControllerMay 04Option Exercise86.5280969,99515,741May 06 04:27 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 04Sale260.872,330607,82726,838May 06 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 04Sale260.862,330607,80328,902May 06 04:17 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 04Sale260.761,553404,95735,179May 06 04:38 PM
Silva Paul MSVP & ControllerMay 04Sale260.87809211,04814,932May 06 04:27 PM
Sachdev AmitEVP, Chief Patient OfficerMay 04Sale262.2843,75211,475,17935,103May 06 04:43 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffApr 29Option Exercise90.292,125191,86628,963May 01 04:22 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffApr 29Sale254.952,125541,76926,838May 01 04:22 PM
Lee YuchunDirectorApr 28Option Exercise57.271,12564,4293,000Apr 29 04:14 PM
Lee YuchunDirectorApr 28Sale257.881,125290,1151,875Apr 29 04:14 PM
Lee YuchunDirectorApr 27Option Exercise57.272,000114,5403,875Apr 28 04:23 PM
Lee YuchunDirectorApr 27Sale271.212,000542,4191,875Apr 28 04:23 PM
Lee YuchunDirectorApr 24Option Exercise57.272,000114,5403,875Apr 28 04:23 PM
Lee YuchunDirectorApr 24Sale268.142,000536,2861,875Apr 28 04:23 PM
Lee YuchunDirectorApr 23Option Exercise57.272,000114,5403,875Apr 24 04:17 PM
Lee YuchunDirectorApr 23Sale272.532,000545,0521,875Apr 24 04:17 PM
Lee YuchunDirectorApr 22Option Exercise57.272,000114,5403,875Apr 24 04:17 PM
Lee YuchunDirectorApr 22Sale267.882,000535,7531,875Apr 24 04:17 PM
Lee YuchunDirectorApr 21Option Exercise57.272,000114,5403,875Apr 22 04:14 PM
Lee YuchunDirectorApr 21Sale266.762,000533,5231,875Apr 22 04:14 PM
Lee YuchunDirectorApr 20Option Exercise57.272,000114,5403,875Apr 22 04:14 PM
Lee YuchunDirectorApr 20Sale273.162,000546,3101,875Apr 22 04:14 PM
Silva Paul MSVP & ControllerApr 13Option Exercise90.2985977,55915,791Apr 15 04:15 PM
Silva Paul MSVP & ControllerApr 13Sale248.72859213,65014,932Apr 15 04:15 PM
Silva Paul MSVP & ControllerApr 06Option Exercise155.574,891760,89319,823Apr 08 04:17 PM
Silva Paul MSVP & ControllerApr 06Sale255.574,8911,249,99314,932Apr 08 04:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 25Sale233.413,028706,77628,902Feb 26 04:29 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 25Sale233.743,634849,41835,179Feb 26 04:30 PM
Kewalramani ReshmaEVP and CMOFeb 25Sale233.453,634848,37126,626Feb 26 04:32 PM
LEIDEN JEFFREY MCEO & PresidentFeb 25Sale233.4610,5502,463,04692,581Feb 26 04:34 PM
Parini MichaelEVP, CL&AOFeb 25Sale233.493,028707,00526,838Feb 26 04:35 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 25Sale233.533,376788,40232,915Feb 26 04:36 PM
Silva Paul MSVP & ControllerFeb 25Sale233.451,080252,12714,932Feb 26 04:37 PM
Tatsis OuraniaSVP, CROFeb 25Sale233.171,296302,18712,738Feb 26 04:39 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale243.673,128762,20134,346Feb 19 04:31 PM
Kewalramani ReshmaEVP and CMOFeb 18Sale243.511,183288,07033,158Feb 19 04:33 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 18Sale243.563,128761,84241,711Feb 19 04:32 PM
LEIDEN JEFFREY MCEO & PresidentFeb 18Sale243.5211,6852,845,518111,541Feb 19 04:35 PM
Parini MichaelEVP, CL&AOFeb 18Sale243.613,128762,02032,282Feb 19 04:36 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 18Sale243.563,489849,78039,447Feb 19 04:37 PM
Silva Paul MSVP & ControllerFeb 18Sale243.581,564380,95716,876Feb 19 04:38 PM
Tatsis OuraniaSVP, CROFeb 18Sale243.621,279311,58515,070Feb 19 04:39 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale246.1117,0324,191,77139,970Feb 12 05:11 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 11Sale246.0911,2862,777,32547,335Feb 12 05:13 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale246.0947,52311,694,933132,540Feb 12 05:19 PM
Parini MichaelEVP, CL&AOFeb 11Sale246.1116,8824,154,83237,906Feb 12 05:20 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 11Sale246.0813,0703,216,31146,198Feb 12 05:22 PM
Silva Paul MSVP & ControllerFeb 11Sale246.045,8621,442,30119,688Feb 12 05:24 PM
Lee YuchunDirectorFeb 10Option Exercise57.271,18167,6363,056Feb 12 05:14 PM
Lee YuchunDirectorFeb 10Sale242.511,181286,4031,875Feb 12 05:14 PM
Lee YuchunDirectorFeb 07Option Exercise57.272,000114,5403,875Feb 11 04:17 PM
Lee YuchunDirectorFeb 07Sale237.822,000475,6431,875Feb 11 04:17 PM